![Dorothea Klein](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Dorothea Klein
Career history of Dorothea Klein
Former positions of Dorothea Klein
Companies | Position | Start | End |
---|---|---|---|
Abraxis BioScience, Inc.
![]() Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | Human Resources Officer | - | - |
ANSELL LIMITED | Human Resources Officer | 2011-01-19 | - |
Training of Dorothea Klein
Hochschule Reutlingen | Undergraduate Degree |
Statistics
International
Australia | 2 |
United States | 2 |
Germany | 2 |
Operational
Human Resources Officer | 2 |
Undergraduate Degree | 1 |
Sectoral
Producer Manufacturing | 2 |
Health Technology | 2 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
ANSELL LIMITED | Producer Manufacturing |
Private companies | 1 |
---|---|
Abraxis BioScience, Inc.
![]() Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | Health Technology |
- Stock Market
- Insiders
- Dorothea Klein
- Experience